Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

Launched by AUSTRIAN MIGRAINE REGISTRY COLLABORATION · Mar 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of monoclonal antibodies, which are special types of medications, to help prevent migraines. These medications, specifically erenumab, fremanezumab, and galcanezumab, are prescribed by doctors to patients who have either episodic migraines (which occur less frequently) or chronic migraines (which happen more often). The trial aims to understand how safe these treatments are in everyday life, how effective they are for people experiencing migraine auras (visual disturbances that can happen before a migraine), and whether patients benefit from switching between different monoclonal antibodies.

To participate in this study, individuals must be aged 18 or older and have a diagnosis of episodic or chronic migraines with or without aura. They should also be receiving one of the listed monoclonal antibody treatments as prescribed by their doctor. Participants can expect to share their experiences and any changes in their migraines while using these medications. It’s important to note that this study is not looking at medications being used in any way other than how they are officially prescribed. If you're interested in taking part, please talk to your healthcare provider to see if you qualify!

Gender

ALL

Eligibility criteria

• • Inclusion Criteria (all of the follwing)
• • episodic or chronic migraine with or without aura
• • erenumab, fremanezumab or galcanezumab is prescribed as a standard of care treatment by treating physician Eptinezumab may be included as soon as available in Austria.
• Exclusion Criteria:
• • • Off label use of erenumab, fremanezumab or galcanezumab